Analysis of the Effects of Ulinastatin Combined with Cefoperazone-Sulbactam on PCT and WBC in the Treatment of Severe Pneumonia in Elderly ICU Patients

LIN Heyan

doi:10.13919/j.issn.2095-6274.ZHJY202406012

Abstract：Objective To explore the value of ulinastatin combined with cefoperazone-sulbactam sodium in the treatment of elderly patients with severe pneumonia in the ICU.Methods 100 elderly patients with severe pneumonia admitted to the ICU of Hainan Sanya Harbin Medical University Hongsen Hospital from March 2023 to March 2024 were included in the study.They were randomly divided into the study group and the control group,with 50 patients in each group.The study group was treated with ulinastatin combined with cefoperazone-sulbac-tam sodium,while the control group was treated with cefoperazone-sulbactam sodium alone.Procalcitonin(PCT)and white blood cell(WBC)levels,clinical symptom recovery time,clinical efficacy,and adverse reactions were compared between the two groups.Results Before treatment,there were no significant differences in PCT and WBC levels between the two groups(P＞0.05).After treatment,PCT and WBC levels decreased in both groups(P＜0.001),while the study group showed significantly lower levels of PCT and WBC than those of the control group(P＜0.001).The study group had significantly shorter fever reduction time,lung inflammation absorption time,and sputum color change time compared to the control group(P＜0.001).The clinical efficacy rate in the study group was 98.00％,significantly higher than that(84.00％)in the control group(P＜0.05).The incidence of adverse re-actions in the study group was 8.00％,which compared to that(10.00％)in the control group,has no significant difference(P＞0.05).Conclusions The combination of ulinastatin and cefoperazone-sulbactam sodium is effec-tive in treating elderly ICU patients with severe pneumonia,as it significantly reduces PCT and WBC levels,short-ens clinical symptom recovery time,has a remarkable clinical efficacy,and carries a low risk of adverse reactions.